Avirup Guha

Jan 10, 2025 | sciencedirect.com | Sara Tyebally |Avirup Guha |Derya Tilki |Philip Cornford

© 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Jul 25, 2024 | cancernetwork.com | Heather Moore |Avirup Guha |Irene Arias |Stella Stergiopoulos |Benjamin Li |Michael G. Fradley | +3 more

BackgroundThe prevalence of preexisting cardiovascular (CV) comorbidities at diagnosis of hormone receptor-positive (HR+)/HER2-negative (HER2–) metastatic breast cancer (mBC) has not been well established. We aimed to describe the prevalence of preexisting CV comorbidities in patients with newly diagnosed HR+/HER2– mBC and to describe the first documented cancer treatment and concurrent medications with risk of QT interval (QTc) prolongation for patients with or without CV comorbidities.

Jun 22, 2024 | acsjournals.onlinelibrary.wiley.com | Susan Dent |Robin Tumlinson |Avirup Guha |Heather Moore

CONFLICT OF INTEREST STATEMENT Susan Dent reports consulting for AstraZeneca, Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Gilead Sciences, Eli Lilly, and Novartis. Avirup Guha reports being a ZERO Cancer Health Equity Task Force member, American Heart Association Council on Clinical Cardiology and Genomics and Precision Medicine Cardio-Oncology Committee member and site principal investigator, and Myovant, Pfizer, and Novartis Advisory Board member.